Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma
Overview
Authors
Affiliations
Pancreatic ductal adenocarcinoma (PDA) is characterized by a pronounced fibroinflammatory stromal reaction consisting of inordinate levels of hyaluronan (HA), collagen, immune cells, and activated fibroblasts that work in concert to generate a robust physical barrier to the perfusion and diffusion of small molecule therapeutics. The targeted depletion of hyaluronan with a PEGylated recombinant human hyaluronidase (PEGPH20) lowers interstitial gel-fluid pressures and re-expands collapsed intratumoral vasculature, improving the delivery of concurrently administered agents. Here we report a non-invasive means of assessing biophysical responses to stromal intervention with quantitative multiparametric magnetic resonance imaging (MRI) at 14 Tesla (T). We found that spin-spin relaxation time T2 values and glycosaminoglycan chemical exchange saturation transfer (GagCEST) values decreased at 24 h, reflecting depletion of intratumoral HA content, and that these parameters recovered at 7 days concurrent with replenishment of intratumoral HA. This was also reflected in an increase in low-b apparent diffusion coefficient (ADC) at 24 h, consistent with improved tumor perfusion that again normalized at 7 days after treatment. Phantom imaging suggests that the GagCEST signal is driven by changes in HA versus other glycosaminoglycans. Thus, multiparametric magnetic resonance imaging (MRI) can be used as a non-invasive tool to assess therapeutic responses to targeted stromal therapy in PDA and likely other stroma-rich solid tumors that have high levels of hyaluronan and collagen.
Liao H, Yuan J, Liu C, Zhang J, Yang Y, Liang H Radiol Med. 2024; 129(11):1559-1574.
PMID: 39412688 DOI: 10.1007/s11547-024-01902-y.
The role and mechanism of compressive stress in tumor.
Tan M, Song B, Zhao X, Du J Front Oncol. 2024; 14:1459313.
PMID: 39351360 PMC: 11439826. DOI: 10.3389/fonc.2024.1459313.
Arias-Lorza A, Costello J, Hingorani S, Von Hoff D, Korn R, Raghunand N Sci Rep. 2024; 14(1):11570.
PMID: 38773189 PMC: 11109088. DOI: 10.1038/s41598-024-62470-9.
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.
Hartupee C, Nagalo B, Chabu C, Tesfay M, Coleman-Barnett J, West J Front Immunol. 2024; 15:1287459.
PMID: 38361931 PMC: 10867137. DOI: 10.3389/fimmu.2024.1287459.
Reeves E, Li J, Zormpas-Petridis K, Boult J, Sullivan J, Cummings C Mol Oncol. 2023; 17(6):1076-1092.
PMID: 37081807 PMC: 10257424. DOI: 10.1002/1878-0261.13437.